Author Archives: Patricia Inacio PhD

Phase 2 Trial of Oral ANVS401 Can Continue, Safety Board Says

A Phase 2 clinical trial testing Annovis Bio’s oral therapy ANVS401 (also known as Posiphen) in people with early Alzheimer’s disease can continue without changes, according to a positive review by the study’s independent Data Safety Monitoring Board (DSMB). The DSMB reviewed safety data, enrollment, participant status,…

Scientists Identify Compounds That Can Protect Brain Mitochondria From Damage Associated With Alzheimer’s

A new screening assay has identified small molecules capable of protecting brain mitochondria from stress conditions that commonly occur in Alzheimer’s and other neurodegenerative diseases. These preclinical results in mice support the therapeutic potential of these newly discovered compounds. The study, “Neuron-based high-content assay and screen for CNS…